Duration of immunosuppressive treatment for chronic graft-versus-host disease.
about
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsExtracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsExtracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsPhysical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patientsGraft-versus-host disease: why have we not made more progress?MHC haplotype matching for unrelated hematopoietic cell transplantation.Acquired immunologic tolerance: with particular reference to transplantationRationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHDTreatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD ConsortiumChronic graft-versus-host disease (GVHD) in children.Failure-free survival after initial systemic treatment of chronic graft-versus-host diseaseAllogeneic hematopoietic cell transplantation: the state of the artComparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.Mesenchymal stem cell as salvage treatment for refractory chronic GVHDHave we made progress in the management of chronic graft-vs-host disease?Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.High-dose cyclophosphamide for graft-versus-host disease prevention.Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host diseaseCenter for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohortTolerance associated gene expression following allogeneic hematopoietic cell transplantation.Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation.Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease.Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host diseaseTreatment of chronic graft-versus-host disease: Past, present and future.The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortalityLong-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesWho is fit for allogeneic transplantation?Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium studyProlonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseVariation in management of immune suppression after allogeneic hematopoietic cell transplantation.Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
P2860
Q24187102-2D4A1D94-0621-45A7-9C4C-93A7B69146AFQ24200272-DD42F9D5-7587-46E9-B79B-D4A1B713B433Q24202963-352AED84-BB55-4018-B110-7B02DC58DDEBQ26787230-ED53F474-DFD9-4472-B2C4-3A5C10727566Q27012940-A91F9A0F-44DF-4570-8BDC-7A8E50DC8394Q33279672-29BB860F-18DF-41C3-91E8-3933EAEAAA30Q33567138-D16DC6A9-F47F-4788-A024-45BBBA375D46Q33591662-344F8F2A-2382-4A66-B5E8-65C75EBC63ECQ33608255-CAA56310-388C-4E38-87FB-A3BB6673DDDCQ33830644-3FE6A096-C0A1-442E-9B39-B0941143270BQ33857680-B69C99BC-2C27-4961-A374-5172107E76B3Q34077787-B52A7143-C0B0-4A2E-8AA8-F25026202A8FQ34145155-2F6E903C-1B87-438F-9F8E-303C247C94F3Q34279929-C2ED5A29-6C21-4B1C-95D1-85DCF4506083Q34562177-1B948B46-85DE-4D73-8AD8-3618912299A7Q34644980-FF471855-4C50-4E64-8D03-AD15659AB529Q35067642-CC3BF737-20D9-47C4-876B-D767C0B29352Q35078368-EB12F463-F4C2-4F45-9378-F14A2182F41DQ35085226-ACB178A5-497A-4746-AA7C-DEF3F86F9F3FQ35110765-20F5FEE3-84F5-4A5F-A439-32C0DB36AEA2Q35112269-52AFD814-EA90-4729-80FE-2DA34EE37488Q35176287-EA96B737-1000-4B8F-8A12-9286E799AE9EQ35177449-E663656A-6C15-44AA-9FC0-FD269D02574DQ35182401-5B8CC2E4-3132-434D-80C0-003909251EAAQ35193740-84EF9515-F91D-4271-BC48-B9217FDA8AC5Q35224947-C8080E5F-C16A-4940-88D9-02E7C2D7963DQ35224975-07B51BEB-ABF5-454A-8C30-78D81D611687Q35266002-0ED2FECB-93AC-4197-B58E-80B2E5D35D83Q35483810-F2652BFA-C49E-48E1-8F7D-09B528F622CDQ35485880-48D04067-B244-41CB-9C6E-963FFA9DB68EQ35524687-FE2E7DA9-6554-482B-AB2A-0F2DA2929E07Q35528671-2B020F36-724D-4657-97A1-FF8E112E8EDBQ35554703-F3B018F9-255E-4772-8AED-B80D9DAD4844Q35660739-77269650-569D-42EF-8147-A16B6DB6C40CQ35794478-ED14CCB2-A770-4ECF-82A0-0A3B70D3D2CCQ35800856-546082AE-F3F0-4282-B84E-891991AF4178Q35836321-E47BDA65-DB5D-4B7C-8ED5-3A11E0146033Q35848407-C2594065-E0F8-4CBF-B7BD-16AE96F33A47Q35849241-8391AFA0-8001-48B9-980F-252696E7F83EQ35849423-EE5686F2-61F6-4A52-A3E1-757A65068FF8
P2860
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@en
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@nl
type
label
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@en
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@nl
prefLabel
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@en
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@nl
P2093
P50
P1433
P1476
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
@en
P2093
A James Morton
Betty L Stewart
Carina Moravec
Claudio Anasetti
Effie W Petersdorf
Hans-Peter Kiem
Jan Storek
Jean E Sanders
John A Hansen
Mary E D Flowers
P304
P356
10.1182/BLOOD-2004-01-0200
P407
P577
2004-08-03T00:00:00Z